Left ventricular mass predicts cardiac reverse remodelling in patients treated with empagliflozin Niveditha Subramani4 July 2023 11:15 AM ISTLeft ventricular hypertrophy (LVH) is an established predictor of poor cardiovascular outcomes, while increases in left ventricular mass indexed...
FDA approves new oral therapy for treatment of Type 2 Diabetes in children Dr. Kamal Kant Kohli22 Jun 2023 9:45 AM ISTUSA: The US Food and Drug Administration (FDA) has approved empagliflozin (Jardiance, Boehringer Ingelheim) and empagliflozin combined with metformin...
Eli Lilly-Boehringer Ingelheim bags USFDA nod for Type 2 diabetes drugs Jardiance, Synjardy for children Ruchika Sharma21 Jun 2023 4:30 PM ISTUnited States: The U.S. Food and Drug Administration (FDA) on Tuesday approved Eli Lilly and partner Boehringer Ingelheim's drugs Jardiance and...
Empagliflozin use feasible for HFpEF patients whether or not they are taking diuretics: JAMA Medha Baranwal29 May 2023 11:15 AM ISTUSA: Empagliflozin treatment in patients with heart failure and preserved ejection fraction (HFpEF) is similar regardless of diuretic dose or use; and...
Empagliflozin reduces heart failure events across spectrum of CKD: Analysis of EMPEROR trials Medha Baranwal11 May 2023 10:45 AM ISTUSA: Empagliflozin (Jardiance) consistently reduced heart failure (HF) events across the spectrum of chronic kidney disease (CKD), according to...
Eli Lilly-Boehringer's Jardiance for children with type 2 diabetes accepted by USFDA Ruchika Sharma10 March 2023 12:23 PM ISTIndianapolis: Boehringer Ingelheim and Eli Lilly and Company have announced that the U.S. Food and Drug Administration (FDA) has accepted a...
Empagliflozin tied to meaningful reduction of HbA1c compared to linagliptin in young diabetes patients: Lancet Jacinthlyn Sylvia9 March 2023 11:15 AM ISTA new study published in The Lancet Diabetes & Endocrinology suggests that linagliptin did not reduce HbA1c in a clinically meaningful way,...
SGLT2 inhibitor empagliflozin could be new treatment option for children with type 2 diabetes: Lancet Dr. Kamal Kant Kohli4 March 2023 11:00 AM ISTUSA: Empagliflozin could be a new treatment option for children and adolescents with type 2 diabetes, findings from a phase 3 clinical trial have...
Medical Bulletin 25/February/2023 Isra Zaman25 Feb 2023 2:45 PM ISTHere are the top medical news for the day: Oral empagliflozin provided safe glycemic control in children with type 2 diabetes: Phase 3 trial...
Oral empagliflozin provided safe glycemic control in children with type 2 diabetes: Phase 3 trial findings Isra Zaman25 Feb 2023 9:00 AM ISTResearchers led by pediatric endocrinologists at Joslin Diabetes Center recently completed a phase 3 clinical trial that assessed the efficacy and...
Empagliflozin promising in hyponatremia induced by Chronic Syndrome of Inappropriate Antidiuresis Dr Kartikeya Kohli10 Feb 2023 11:30 AM ISTSwitzerland: According to clinical research on acid-base and electrolyte disorders, the sodium-glucose cotransporter 2 (SGLT2) inhibitor...
USFDA accepts supplemental New Drug Application for Jardiance for adults with chronic kidney disease: Eli Lilly Ruchika Sharma22 Jan 2023 12:00 PM ISTIndianapolis: The U.S. Food and Drug Administration (USFDA) has accepted a supplemental New Drug Application (sNDA) for Jardiance (empagliflozin)...
